Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Insights Into the Recognition and Management of SGLT2-Inhibitor-Associated Ketoacidosis: It's Not Just Euglycemic Diabetic Ketoacidosis.

× No keyword cloud information.

8 in total

1. A Case of Euglycemic Diabetic Ketoacidosis Triggered by a Ketogenic Diet in a Patient With Type 2 Diabetes Using a Sodium-Glucose Cotransporter 2 Inhibitor.

Authors: Paola Sanchez Garay; Gabriela Zuniga; Robert Lichtenberg
Journal: Clin Diabetes Date: 2020-04

Review 2. Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks.

Authors: Rachel J Perry; Gerald I Shulman
Journal: J Biol Chem Date: 2020-08-12 Impact factor: 5.157

3. Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: A systematic review and quantitative analysis.

Authors: Siddhartha Dutta; Tarun Kumar; Surjit Singh; Sneha Ambwani; Jaykaran Charan; Shoban B Varthya
Journal: J Family Med Prim Care Date: 2022-03-10

4. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature.

Authors: Alexis Diaz-Ramos; Wesley Eilbert; Diego Marquez
Journal: Int J Emerg Med Date: 2019-09-05

5. Basal insulin secretion capacity predicts the initial response and maximum levels of beta-hydroxybutyrate during therapy with the sodium-glucose co-transporter-2 inhibitor tofogliflozin, in relation to weight loss.

Authors: Yuichi Sato; Kiyohide Nunoi; Kohei Kaku; Akihiro Yoshida; Hideki Suganami
Journal: Diabetes Obes Metab Date: 2019-11-14 Impact factor: 6.577

Insights Into the Recognition and Management of SGLT2-Inhibitor-Associated Ketoacidosis: It's Not Just Euglycemic Diabetic Ketoacidosis.

1. A Case of Euglycemic Diabetic Ketoacidosis Triggered by a Ketogenic Diet in a Patient With Type 2 Diabetes Using a Sodium-Glucose Cotransporter 2 Inhibitor.

Review 2. Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks.

3. Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: A systematic review and quantitative analysis.

4. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature.

5. Basal insulin secretion capacity predicts the initial response and maximum levels of beta-hydroxybutyrate during therapy with the sodium-glucose co-transporter-2 inhibitor tofogliflozin, in relation to weight loss.

6. [Confusion, tachypnea, and tachycardia in a 71-year-old man with type 2 diabetes mellitus].

Review 7. SGLT2 Inhibitors, What the Emergency Physician Needs to Know: A Narrative Review.

8. Euglycemic Diabetic Ketoacidosis in the ICU: 3 Case Reports and Review of Literature.